Supplementary Note 1 Challenge Design
Due to the rapid pace of new technology introduction, algorithm development for interpreting NGS results has been forced to adapt quickly. This has led to a situation in which both the sequencing characterization and the analysis software have been poorly characterized in terms of their error profiles, which can confound their use in both discovery and clinical applications. Here we report the development of BAMSurgeon to generate robust in silico tumour-normal pairs, and its use with crowd-sourcing to provide the largest benchmark of somatic SNV-calling methods to date. Challenges incentivize collaboration, can lead to innovative solutions or to the identification of new problems that can become fodder for new Challenges, accelerate learning, help establish community-standards, allow objective prioritization of methods and help build a community of researchers around specific and timely problems. There has been a growing trend in the use of crowd-sourcing to stimulate research in specific areas 1 , and DREAM (Dialogue for Reverse Engineering Assessment and Methods) has been a leader in promoting this approach across multiple problem domains. Recent and ongoing DREAM Challenges in systems biology are promoting rigorous performance assessment, development of standards and demonstrating how ensemble methods sampled across community predictions can improve upon the work of any individual group. Thus structuring benchmark development as a Challenge incentivized collaboration and rapid learning, and allowed the Challenge community to assess a broad cross-section of current methods efficiently.
The SMC Challenge includes two components (Supplementary Figure 1) . To encourage participation from researchers in alternate fields, we simulated five synthetic tumours (subChallenges 2A-1 to 2A-5 and 2B-1 to 2B-5) of increasing difficulty and created corresponding leaderboards to provide real-time feedback. These five sub-Challenges allow for algorithm training prior to the main Challenge (Intel-10 SNV sub-Challenge and ITM1-10 SV subChallenge) in which we provided 10 tumour/normal pairs from real patients (five samples derived from prostate cancers and five derived from pancreatic cancers). It is ensured that participants have approval of data access by the ICGC Data Access Compliance Office. To validate performance on the real tumours, thousands of predicted variants will be sequenced using Ion Torrent, an independent sequencing technology. These two stages will allow for benchmarking of somatic single-nucleotide and structural variation prediction on synthetic and patient-derived datasets. Upon completion of the Challenge, the best performing methods will be made available to the community as validated open source pipelines.
The Challenge is run on the Synapse (www.synapse.org) open computational platform. Synapse serves not just as a data repository but also as a framework for conducting collaborative analysis and sharing and documenting data, models and analysis methods. Synapse enables researchers to seamlessly and transparently conduct, track and share their ongoing work -building up living research projects in real-time. GeneTorrent client, an open--source software developed by Annai Systems, is available for local data download. A comprehensive description of GeneTorrent features and operation is available on the CGHub website: https://cghub.ucsc.edu/docs/user/index.html. Google is offering Google Cloud Platform credits of $2,000 to approved Challenge participants, including free access to contest data in Google Cloud Storage. These credits can be used for Compute Engine VMs and other Cloud Platform services. Futhermore, free access to Challenge data is provided via a Google Cloud Storage bucket, so all computation and submissions can be performed on the Google Cloud Platform.
Overall Challenge Findings
While we have reported here only the results of the first three SMC Challenge tumours, participation remains high; to date 387 registrants have submitted 3,132 analyses of 14 genomes. Our analysis of the results from the first SMC Challenge tumour has yielded several important discoveries. First, it has confirmed the widely suspected inter-regional variability in error-rates, where variant-calling tool-chains have been optimized towards coding regions. As increasing numbers of functional non-coding SNVs are identified 2 , algorithm-developers will be able to use tools like BAMSurgeon to develop algorithms with improved accuracy outside of coding regions. Second, the large number of submissions allowed for robust statistical modeling of the sequence-characteristics associated with errors. False-positives and false-negatives showed distinct characteristics, with only a few variables (e.g. mapping quality, normal coverage and base quality) being important for both --this may guide the quality-evaluation of clinicallytargeted sequencing. Third, our results provide clear evidence that ensemble-based approaches comprised of existing algorithms may be an effective way to improve prediction accuracies, as shown in several other areas of biology by other DREAM Challenges [3] [4] [5] , and hinted at previously for somatic mutation calling 6 . Fourth, we have shown that sequencing-errors can closely resemble real biological discoveries. Ongoing stages of the challenge address structural variants and short indels in synthetic tumor-normal pairs. Analysis of the synthetic phases will be used to guide later stages of the Challenge when the algorithms are applied to real tumor/normal pairs. Finally, comparison of synthetic and real results will feed back into BAMSurgeon development efforts, improving the fidelity with which synthetic reads can be generated.
An unexpected outcome of this Challenge was an improvement in our ability to accurately simulate tumour-normal genomes. Challenge contestants continually offered suggestions (including source-code patches and detailed statistical analyses) to enhance BAMSurgeon's simulations. This highlights the value of open-science to foster incremental communityimprovements that yield robust tools of broad benefit.
No algorithm perfectly predicts somatic SNVs on even the simplest tumour (IS1) --the best team achieved an F-score of 0.975. This is high enough to lead to significant artifacts in downstream analyses as errors are non-randomly distributed. Surprisingly, reduced tumourcellularity did not significantly alter error-rates (IS2), but sub-clonality did: the best methods achieved F-scores of ~0.95 in IS3. These data strongly suggest that there remains significant room to improve somatic SNV prediction algorithms.
Supplementary Note 2 Related Work
Existing methods for simulating cancer genomes generally fall into one of two categories: (1) simulating reads from a reference genome assembly or (2) spiking in sequence reads that support known bona fide mutations into an alignment that lacks the spiked-in mutations. The first approach is exemplified by a number of software tools, the most widely used is perhaps the wgsim utility , among others. Each of these has varying parameters and some include simulation of error models for some subset of sequencing technologies. Examples of the second approach where reads from one sample are 'spiked-in' to another include the SomaticSpike tool used to evaluate the MuTect somatic mutation detection method 12 , and the datasets generated for the SMaSH benchmarking toolkit 13 . These two general approaches (read simulation and spike-in of 'real' mutations) both have their merits and demerits; for example, simulating reads can simulate any underlying genome mutation or rearrangement as the reference from which the simulated reads are generated serves as the 'ground truth'. The primary drawback is that simulated reads cannot recapitulate biases and error profiles if they are not completely known for a given combination of sequence technology and sample preparation method -this is a reasonably serious drawback given that the sequencing method is a fundamental source of error in mutation calls and it is unlikely that the error profile of any given combination of sequencing method and sample preparation method is completely specified in a way amenable to simulation approaches. Using reads from actual sequencing results that support known mutations provides a clear route around this drawback, but with the disadvantage that the sites of spiked-in mutations must come from known mutations: any arbitrary site in the genome is unlikely to be the site of a mutation present in dbSNP 14 , COSMIC 15 (cancer.sanger.ac.uk), or other sources of bona fide validated mutations. Put another way, any 'spike-in' mutation must have been detectable by some means, therefore simulations using this method could conceivably be biased towards mutations already detectable by existing mutation callers, thereby limiting the development of callers with improved sensitivity. BAMSurgeon bridges these two general approaches to mutation simulation by providing a third alternative: modifying preexisting alignments and realigning the modified reads. Through this approach, any arbitrary site with adequate read coverage (as defined by the user) can be mutated, and the underlying error profile stemming from the sequencing technology and sample preparation method will be realistic. 
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Supplementary Figure 1: Challenge Structure
The SMC Challenge consists of two parts. The main challenge (Intel-10 SNV Sub-Challenge and ITM1-10 SV Sub-Challenge) consists of human tumour data derived from real patients -ten tumour/normal paired samples. The second challenge (2A-1 to 2A-5 and 2B-1 to 2B-5), proceeding the real data in timeline, consists of five synthetic datasets increasing in difficulty to allow participants to train their tools prior to the real tumour challenge.
Supplementary Figure 2: Effect of Read Split on Tool Performance
To test the robustness of BAMSurgeon to read split, we compared the rank of Radia (yellow), MuTect (dark blue), SomaticSniper (light blue) and Strelka (light green) on a tumour/normal paired dataset with alternate read splitting. Radia and SomaticSniper retained the top two positions while MuTect and Strelka remained third and fourth, regardless of read split.
Supplementary Figure 3: Overview of SMC-DNA in silico Challenges 2 and 3 Datasets
Precision-recall plot for all entries to IS2 -colours represent individual teams, and the best submission from each team by Fscore is outlined (A). We evaluated the performance of an ensemble somatic SNV predictor by taking the majority vote of calls made by a subset of the top performing submissions on IS2 and IS3. Ensemble models created and tested on IS2 -colours represent individual submissions while the gray dots represent the ensemble model (B). Precision-recall plot for all entries to IS3 (C). Ensemble models created and tested on IS3 (D).
Supplementary Figure 4: Precision and Recall of Ensemble Classifier
An ensemble classifier of subsets ranging from 1 to 119 algorithms selected from the IS1 submissions was developed taking calls with the majority vote across incorporated algorithms. The precision (A) and recall (B) of the ensemble classifier (grey) was compared to the values of the individual submissions (coloured). Dot colour reflects the submitting team. The ensemble classifier was found to have higher recall and precision than majority of the individual submissions. Similar plots are shown for IS2 precision (C) and recall (D), as well as IS3 precision (E) and recall (F).
Supplementary Figure 5: Permutation Analysis of Ensemble Robustness
To evaluate the robustness of the IS1 ensemble classifier we randomly sampled algorithms at each subset size 1,000 times and evaluated performance (A). The distribution of performance at each size threshold reflected the performance seen by subsetting the top scoring algorithms giving evidence for the robustness of the method. To better visualize false positive and false negative relationship, some points that exceeded the limits of the scatterplots were omitted.
